Camurus Past Earnings Performance

Past criteria checks 2/6

Camurus has been growing earnings at an average annual rate of 71.8%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 45.3% per year. Camurus's return on equity is 8.6%, and it has net margins of 15.8%.

Key information

71.8%

Earnings growth rate

72.6%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate45.3%
Return on equity8.6%
Net Margin15.8%
Next Earnings Update13 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Camurus makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:CAMR.F Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,689266531746
30 Jun 241,593223497731
31 Mar 241,823450449718
31 Dec 231,717431424638
30 Sep 231,610460383543
30 Jun 231,468408356502
31 Mar 231,020115330457
31 Dec 2295656309474
30 Sep 2287128289445
30 Jun 22784-13268422
31 Mar 22695-69249423
31 Dec 21601-90240389
30 Sep 21523-142275355
30 Jun 21470-156285319
31 Mar 21413-128275252
31 Dec 20336-167269239
30 Sep 20265-174214229
30 Jun 20205-216197246
31 Mar 20136-284198263
31 Dec 19106-290194249
30 Sep 1978-305192248
30 Jun 1958-286168235
31 Mar 1953-266145225
31 Dec 1849-235123208
30 Sep 1847-200100194
30 Jun 1840-20893205
31 Mar 1852-18780206
31 Dec 1754-19172223
30 Sep 1786-16664234
30 Jun 17104-12755209
31 Mar 17111-10249191
31 Dec 16114-8143172
30 Sep 16113-8529154
30 Jun 16120-9526156
31 Mar 16116-18931151
31 Dec 15155-16031153
30 Sep 15263-5342153
31 Dec 142084834114
31 Dec 13198992253

Quality Earnings: CAMR.F has high quality earnings.

Growing Profit Margin: CAMR.F's current net profit margins (15.8%) are lower than last year (28.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CAMR.F has become profitable over the past 5 years, growing earnings by 71.8% per year.

Accelerating Growth: CAMR.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: CAMR.F had negative earnings growth (-42.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (54.6%).


Return on Equity

High ROE: CAMR.F's Return on Equity (8.6%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 13:08
End of Day Share Price 2024/12/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Camurus AB (publ) is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Oscar Haffen LammBryan Garnier & Co
Alexandru CogutBryan Garnier & Co
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB